Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress

Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance. The activation of Akt by sorafenib is thought to be responsible for this resistance. Bufalin is the major active ingred...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Bo, Hu, Fengli, Yan, Haijiang, Zhao, Dali, Jin, Xin, Fang, Taishi, Pan, Shangha, Sun, Xueying, Xu, Lishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575108/
https://www.ncbi.nlm.nih.gov/pubmed/26381511
http://dx.doi.org/10.1371/journal.pone.0138485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575108/
https://www.ncbi.nlm.nih.gov/pubmed/26381511
http://dx.doi.org/10.1371/journal.pone.0138485

Ejemplares similares